AQ4N: An alkylaminoanthraquinone N-oxide showing bioreductive potential and positive interaction with radiation in vivo

British Journal of Cancer

Volumn 72, Issue 1, 1995, Pages 76-81

  McKeown, S R ^a   Hejmadi, M V ^a   McIntyre, I A ^b   McAleer, J J A ^c  

^a UNIVERSITY OF ULSTER   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c DE MONTFORT UNIVERSITY   (United Kingdom)

Author keywords

Bioreductive drugs; Radiation; Tumour hypoxia

Indexed keywords

1 AZIRIDINO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; 1,4 BIS[[2 (DIMETHYLAMINO N OXIDE)ETHYL]AMINO] 5,8 DIHYDROXY ANTHRACENE 9,10 DIONE; 1,4 BIS[[2 (DIMETHYLAMINO N OXIDE)ETHYL]AMINO] 5,8 DIHYDROXYANTHRAQUINONE; ANTHRAQUINONE DERIVATIVE; CYTOTOXIC AGENT; TIRAPAZAMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; HYPOBARISM; HYPOXIA; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION; RADIATION DOSE FRACTIONATION; REDUCTION; WEIGHT REDUCTION;

ANIMAL; ANTHRAQUINONES; ANTINEOPLASTIC AGENTS; CELL HYPOXIA; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; SUPPORT, NON-U.S. GOV'T;

EID: 0029054994     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.1995.280     Document Type: Article

References (20)

1. ARMTTAGE P, AND BERRY G, (1987). Statistical Methods in Medical Research, 2nd ed, pp. 484-498, Blackwell Scientific Publications: Oxford.
2. BREMNER JCM, STRATFORD U, BOWLER J, AND ADAMS GE, (1990). Biorediictfve drugs and the selective induction of tumour hypoxia. Br. J. Cancer, 61, 717–721.
3. BROWN JM, AND LEMMON MJ, (1991). Tumour hypoxia can be exploited to preferentially sensitize tumours to fractionated irradiation. Int. J. Radiat. Oncol. Biol. Pkys., 26, 457–461.
4. BUSH RS, JENKIN RDT, ALLT WEC, BEALE FA, BEAN H, DENBO AJ, AND PRINGLE JF, (1978). Definite evidence for hypoxic cefis influencing cure in cancer therapy. Br. J. Cancer, 37 (Suppl. III), 302–306.
5. COLE S, STRATFORD U, BOWLER J, NOLAN J, WRIGHT EG, LORIMORE SA, AND ADAMS GE, (1991). Oral (p.o.) dosing with RSU 1069 or RB 6145 maintains their potency as hypoxic cell radiosensitizers and cytotoxins but reduces systemic toxicity compared with parenteral (i.p.) administration in mice. Int. J. Radiat. Oncol. Biol. Pkys., 21, 387–395.
6. DENNY WA, AND WAKELIN LPG, (1990). Kinetics of binding of mitoxantrone, ametantrone and analogues to DNA: Relationship with binding mode and anti-tumour activity. Anti-Cancer Drug Design, 5, 189–200.
7. FAULDS D, BALFOUR JA, CHRISP P, AND LANGTRY HD, (1991). Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the chemotherapy of cancer. Drugs, 41, 400–409.
8. GRAHAM MA, KING LH, WORKMAN P, HENDERSON C, WOLF CR, AND PATTERSON LH, (1993). Identification of cyt P450 2C8 as the major human P450 isoform involved in the bioreduction of the novel anthraquinone di-N-oxide, AQ4N. Br. J. Cancer, 67, (Suppl. XX), 9.
9. GRAU C, AND OVERGAARD J, (1991). Radiosensitizing and cytotoxic properties of mitomycin C in a C3H mouse mammary carcinoma in vivo. Int. J, Radiat. Oncol. Biol. Phys., 20, 265–269.
10. KOCH CJ, (1993). Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin. Cancer Res. 53, 3992–3997.
11. KRUPSKI G, KIEFER F, AND WEIBEL FJ, (1985). Variability in the expression of xenobiotic metabolising enzymes during the growth cycle of rat hepatoma cells. Xenobiotica, 15, 781–787.
12. McALEER JJA, McKEOWN SR, MACMANUS MP, LAPPIN TRJ, AND BRIDGES JM, (1992). Hypobaric hypoxia: A method for testing bioreductive drugs in vivo. Int. J. Radiat. Oncol. Biol. Phys., 23, 551–555.
13. MINCHINTON AI, AND BROWN JM, (1992). Enhancement of the cytotoxicity of SR 4233 to normal and malignant tissues by hypoxic breathing. Br. J. Cancer, 66, 1053–1058.
14. MOORE JV, (1988). The dynamics of tumour cords in an irradiated mouse mammary carcinoma with a large hypoxic cell component Jpn J. Cancer Res. (Gann), 79, 236–243.
15. PATTERSON LH, (1989). Anthraquinone anticancer compounds with (disubstituted amino-N-oxide)alkylamino substituent. UK Patent GB 2 237–283.
16. PATTERSON LH, (1993). Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: A new class of bioreductive agent. Cancer Me tost. Rev. 12, 119–134.
17. PATTERSON LH, CRAVEN MR, FISHER GR, AND TEESDALESPITTLE P, (1995). Aliphatic amine N-oxides of DNA binding agents as bioreductive drugs. Oncol Res. (in press).
18. TROTTER MJ, CHAPLIN DJ, AND OLIVE PL, (1990). Possible mechanisms for intermittent blood flow in the murine SCCVII carcinoma. Int. J, Radiat. Biol., 60, 139–146.
19. WORKMAN P, (1992). Design of novel bioreductive drugs. In: Workman P. (ed.) New approaches in Cancer Pharmacology: Drug Design and Development, pp. 63-74. Springer Berlin.
20. WORKMAN P, AND STRATFORD U, (1993). The experimental development of bioreductive drugs and their role in cancer therapy. Cancer Metast Rev, 12, 73–82.